Enlightenment Research’s Novo Nordisk NVO Stock Holding History

Enlightenment Research’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4,200	Closed	-$97K	–	472
2018 Q4	$97K	Buy	+4,200	New	+$93.3K	0.12%	184

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Enlightenment Research's NVO Position: Q1 2019 in Review

Enlightenment Research sold out of Novo Nordisk (NVO) in Q1 2019, closing a stake of 4,200 shares — an estimated $97K sold.

Enlightenment Research first reported a position in NVO in Q4 2018 and held it in 1 quarter. The position peaked at $97K in Q4 2018. 580 funds tracked by Wall St. Rank hold NVO as of Q1 2019.

Enlightenment Research reported no remaining Novo Nordisk position as of Q1 2019 after selling out during the quarter.
Enlightenment Research sold 4,200 Novo Nordisk shares in Q1 2019, an estimated $97K.
Enlightenment Research first reported a position in Novo Nordisk in Q4 2018 and held it in 1 quarter.
Enlightenment Research's Novo Nordisk position peaked at $97K in Q4 2018.
580 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2019.

Based on Enlightenment Research's 13F filing for Q1 2019, filed 3 May 2019.